Healthcare Industry News: ZLB Behring
News Release - January 8, 2007
CSL Behring Reports Progress on Global Implementation of Name ChangeChange from ZLB Behring to CSL Behring Underway Around the World
KING OF PRUSSIA, Pa.--(HSMN NewsFeed)--CSL Behring today provided an update on its global name change, involving as many as 30 products in each of 70 countries worldwide. The new name, CSL Behring, is now registered in the U.S., Germany, Switzerland and Canada, with other countries following over the next several months.
The renaming program, announced by CSL Behring's parent organization, CSL Limited, last year, will present a consistent and compelling view of the company operating in new and established markets around the world. "CSL has a tradition of innovation with important vaccines and medicines that began 90 years ago and continues to grow," said Peter Turner, President of CSL Behring. "The Behring part of our name originates with Emil von Behring, an innovator with serum therapies who won the first Nobel Prize in Physiology and Medicine. We have changed our name, but remain strongly committed to the company values of innovation, safety and passion for our customers that we are known for."
The quality, type and volume of products that CSL Behring produces are not impacted by this name change. The company will continue to trade as ZLB Behring in some markets until registration with regulatory authorities is complete. CSL Behring is currently in the process of notifying the respective national health authorities regarding the license transfer. No changes to product names will occur. Throughout the year, company signage, product packaging, Internet sites, e-mail addresses and promotional literature will be updated to reflect the new name.
About CSL Behring
CSL Behring is a global leader in the plasma protein biotherapeutics industry. Passionate about improving the quality of patients' lives, CSL Behring manufactures and markets a range of safe and effective plasma-derived and recombinant products and related services. The company's therapies are used in the treatment of immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Other products are used for the prevention of hemolytic diseases in the newborn, in cardiac surgery, organ transplantation and in the treatment of burns. The company also operates one of the world's largest plasma collection networks, ZLB Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit www.cslbehring.com.
Source: CSL Behring
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.